**Specialist Medication Monitoring / Shared Care Agreement**

<Recipient Name>

<Recipient Details>

<Recipient Address>

Date: <Todays date>

Ref:

Dear <Recipient Name>

**Re: Patient Name: <Patient name>**

**NHS Number: <NHS number>**

**Address: <Patient Address>**

**Telephone: <Patient Contact Details>**

Please accept this as 6-months’ notice that we are no longer able to undertake shared care agreements and have served notice of such to the ICB. Please be aware that this will require you to retain monitoring and review of this patient as well as undertake ongoing prescribing of the relevant medication.

The patient is currently prescribed <**INSERT SHARED CARE MEDICATION FROM LIST OF REPEAT MEDICATION BELOW COMPARED TO THE SHARED CARE LIST**>.

<Repeat Templates> \*

Latest **X** blood results are included for your reference.

<Pathology & Radiology Reports(table)>

Due to the escalating pressures on general practice, we can no longer undertake work that would ideally be undertaken solely in secondary care without the appropriate resources and mechanisms in place to support this non-core work.

The patient will be monitored until the date our notice is reached and continue to receive medication from us during this time.

Thank you for your ongoing care of our mutual patients to continue their safe monitoring and prescribing.

Yours sincerely

<Sender name>

**On behalf of <Sender details>**

*\*****Note****: Delete this paragraph, additional medication the patient has on repeat that is not on the shared care list and the pages containing the list of medication commissioned as part of the Shared Care / Specialised Drug Monitoring enhanced service after creating letter to the consultant but before saving and sending.*

**CURRENT MEDICATION ON SHARED CARE AGREEMENTS FROM LINCOLNSHIRE ICB**

|  | **Drug** | **Indication** |
| --- | --- | --- |
| 1 | Apomorphine injection (APO-go)  Shared care protocols will be provided by specialist centre initiating treatment. | Parkinson’s disease |
| 2 | Atomoxetine capsules | Attention Deficit Hyperactivity Disorder (ADHD) |
| 3 | Azathioprine tablets | Immunosuppressant, Dermatology and Inflammatory Bowel Disease. |
| 4 | Calcium based phosphate binders.  Calcium acetate- preferred brand in Lincolnshire Renacet® (other centres may use Phosex®, PhosLo®  Calcium carbonate– preferred brand in Lincolnshire is Adcal® | Hyperphosphataemia associated with renal disease. |
| 5 | Ciclosporin capsules, oral solution (Capimune, Capsorin, Deximune, Neoral)  Lincolnshire protocol covers use for dermatology indications and for renal transplant patients under the care of ULHT based services.  For all other indications shared care protocols will be provided by specialist centre initiating treatment. | Immunosuppressant transplant patients also used in dermatology. |
| 6 | Cinacalcet tablets | Secondary hyperparathyroidism associated with end stage renal disease requiring dialysis and hypercalcaemia of primary hyperparathyroidism or parathyroid carcinoma. |
| 7 | Colomycin nebulised therapy - colistimethate sodium (Colobreathe®, Promixin®)  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Adjunct to standard antibacterial therapy in patients with cystic fibrosis |
| 8 | Denosumab (Prolia®)  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Postmenopausal osteoporosis |
| 9 | Dexamfetamine tablets | ADHD |
| 10 | Donepezil tablets, orodispersible tablets, oral solution | Alzheimer’s disease |
| 11 | Dornase alfa nebuliser solution Treatment usually initiated by centres outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Cystic Fibrosis |
| 12 | Dronedarone tablets | Non-permanent atrial fibrillation |
| 13 | Erythropoietins & Epoetin beta (Neo Recormon®), Darbepoetin alfa (Aranesp®), Epoetin alfa (Eprex®)  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Subcutaneous administration only. |
| 14 | Galantamine tablets, oral solution, modified release | Alzheimer’s disease |
| 15 | Guanafacine tablets | ADHD |
| 16 | Hydroxychloroquine tablets | Rheumatoid arthritis |
| 17 | Ketamine oral solution | Palliative care |
| 18 | Lanreotide injection  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Carcinoid tumours |
| 19 | Lanthanum tablets or sachets | Hyperphosphataemia associated with renal disease. |
| 20 | Leflunomide tablets | Rheumatoid arthritis / psoriatic arthritis |
| 21 | Lisdexamfetamine mesilate capsules | ADHD |
| 22 | Melatonin tablets, capsules and oral solution. | Sleep disorders in children with neuro-developmental disorders. |
| 23 | Memantine tablets and oral solution | Alzheimer’s disease |
| 24 | Mercaptopurine tablets | Inflammatory bowel disease |
| 25 | Methotrexate tablets | Rheumatology/dermatology/respiratory |
| 26 | Methylphenidate (generic or modified release oral formulations) | ADHD |
| 27 | Mycophenolate mofetil  Lincolnshire protocol covers use for renal patients under care of ULHT.  For all other indications shared care protocol will be provided by specialist centre initiating treatment. | Immunosuppressant (post-transplant) |
| 28 | Mycophenolic acid (Myfortic®)  Lincolnshire protocol covers use for renal patients under care of ULHT.  For all other indications shared care protocols will be provided by specialist centre initiating treatment. | Immunosuppressant (post-transplant) |
| 29 | Nabilone capsules  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Neuropathic pain |
| 30 | Octreotide injection  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Symptomatic relief malignant obstruction/ acromegaly. |
| 31 | Riluzole (generic, Rilutek)  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Motor neurone disease |
| 32 | Rivastigmine capsules, oral solution, patches | Alzheimer’s disease |
| 33 | Sevelamer carbonate (Renvela®)  Sevelamer hydrochloride (Renagel®) | Hyperphosphataemia associated with renal disease |
| 34 | Sirolimus tablets or oral solution (Rapamune®)  Lincolnshire protocol covers use for renal patients under care of ULHT.  For all other indications shared care protocol will be provided by specialist centre initiating treatment. | Immunosuppressant (post-transplant) |
| 35 | Somatropin injection – Growth Hormone  Treatment usually initiated by centre outside of Lincolnshire. Shared care protocols will be provided by specialist centre initiating treatment. | Synthetic Growth Hormone – protocols cover use in both children and adults. |
| 36 | Sulfasalazine tablets | Rheumatoid arthritis – shared care protocol and inflammatory bowel disease (prescribing guidance) |
| 37 | Tacrolimus capsules (Adoport® or Prograf®)  Lincolnshire protocol covers use for renal patients under care of ULHT.  For all other indications shared care protocol will be provided by specialist centre initiating treatment. | Immunosuppressant (post-transplant) |
| 38 | Tacrolimus modified-release capsules (Advagraf® or Envarsus®)  Lincolnshire protocol covers use for renal patients under care of ULHT.  For all other indications shared care protocol will be provided by specialist centre initiating treatment. | Immunosuppressant (post-transplant) |
| 39 | Tobramycin nebulised therapy  Shared care protocol will be provided by specialist centre initiating treatment. | Chronic pulmonary pseudomonas infection in cystic fibrosis patients. |
| 40 | Sodium Zirconium Cyclosilicate (Lokelma®) | Hyperkalaemia |